Research

How ncRNAs subvert antibiotic effacacy against bacterial pathogens that plague cystic fibrosis patients

Cystic fibrosis (CF) patients are at high risk for acquiring chronic bacterial lung infections that can lead to progressive lung damage and respiratory failure. Antimicrobial treatment for these bacterial pathogens often has a high failure rate even after 1-2 year treatment regimens. Some of these infections are so intractable in CF patients that they require a lung transplant or experimental bacteriophage therapy in an attempt to save lives.

We are studying why antibiotic treatment of life-threatening lung infections caused by these opportunistic bacterial pathogens so often fails in CF patients and other immune compromised individuals. Studying the mechanisms of antimicrobial resistance in these bacterial pathogens should enable the development of better biomarkers to predict the tenacity of these lung infections and enable more informed selection of more effective treatment options using available antibiotics.

How ncRNAs influence pathogenesis — tuberculosis as a case study

Approximately 20% of the global population is infected with Mycobacterium tuberculosis, the bacterial pathogen that causes tuberculosis (TB). In fact, TB still devastates the developing world. TB is once again the #1 killer by a single infectious agent as COVID-19 mortality has diminished.

M. tuberculosis has evolved to evade being killed by our immune system and antibiotics. We are studying the molecular switches, often in ncRNAs and sORFs, that trigger the changes in M. tuberculosis physiology that facilitate immune evasion and antibiotic survival. This work provides a framework for the design of new and improved therapeutics to more rapidly clear TB infections.

Seeking new antibiotics to treat TB

Treatment of TB remains challenging, especially with the rise of multidrug- and extensively-resistant strains. Stemming from our studies on ncRNAs in TB, we have discovered novel and specific drug targets for development of new antituberculars. Guided by high resolution target structures we are performing proof-of-principle studies that will lay the groundwork for future small molecule screens based on cryo-EM structures to be determined in collaboration with Dr. John Hunt at Columbia University.